Conclusions
PsA, PsA disease, RP
JOINT DISEASE
In this post hoc analysis of data from the phase 3 DISCOVER-2 study of guselkumab-treated biologic-naïve patients with active PsA, earlier (Week 8) DAPSA improvement was a significant predictor of less RP through 2 years. Thus, the early and sustained control of joint disease activity with guselkumab may modify the overall long-term PsA disease trajectory to a milder course.